Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 8/20 | 0.63 |
| ▸ | EGFR | P00533 | 1/20 | 0.63 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.63 |
| ▸ | CRYZ | Q08257 | 1/20 | 0.63 |
| ▸ | VAT1 | Q99536 | 1/20 | 0.63 |
| ▸ | RTN4 | Q9NQC3 | 1/20 | 0.63 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29765941 | 0.89 | KRAS (0.80) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL16647110 | 0.89 | KRAS (0.80) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL19296785 | 0.89 | KRAS (0.80) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL24850578 | 0.85 | KRAS (0.64) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL18128389 | 0.80 | KRAS (0.66) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL19296802 | 0.80 | KRAS (0.58) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL23092339 | 0.80 | KRAS (0.81) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL19695779 | 0.79 | KRAS (0.57) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL24850579 | 0.79 | KRAS (0.69) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL24535334 | 0.79 | KRAS (0.76) | KRASEGFRHMOX2CRYZVAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988357-B2 | Methods for preparation of quinazoline derivatives | ARAXES PHARMA LLC (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170190672-A1 | METHODS FOR PREPARATION OF QUINAZOLINE DERIVATIVES | ARAXES PHARMA LLC | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190672-A1 | METHODS FOR PREPARATION OF QUINAZOLINE DERIVATIVES | TTBK2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TTBK1 | KRAS 1369/4885EGFR 4238/4885HMOX2 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.